SutroVax Stock

sutrovax.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $173.25MM

Developer of conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. The company's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.

Register To Buy and Sell Shares

For more details on financing and valuation for SutroVax, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access SutroVax’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like SutroVax.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Grant Pickering
Founder, President, Chief Executive Officer, Director & Board Member
Jeff Fairman Ph.D
Founder & Vice President of Research
Durga Bobba
Chief Business Officer
Elaine Sun
Chief Financial Officer
Aron Stein Ph.D
Vice President, Regulatory Affairs and Quality Assurance
Paul Sauer
Vice President, Process Development & Manufacturing

Board Members

Cristina Ghenoiu Ph.D
Longitude Capital
Moncef Slaoui Ph.D
Patrick Enright
Longitude Capital
Robert Hopfner Ph.D
NFLS - Pivotal
Francesco De Rubertis Ph.D
Kurt Von Emster
Abingworth Management
Nisha Marathe Ph.D
Roche Venture Fund
Peter Hirth Ph.D
Grant Pickering
Heath Lukatch Ph.D
Patrick Heron
Frazier Healthcare Partners
William Newell JD
Sutro Biopharma

Frequently Asked Questions About SutroVax’s Stock

Can you buy SutroVax’s stock?
SutroVax is not publicly traded on NYSE or NASDAQ in the U.S. To buy SutroVax’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell SutroVax’s stock?
Yes, you can sell stock of a private company like SutroVax. Forge can help you sell your SutroVax stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is SutroVax’s stock price?
SutroVax is a privately held company and therefore does not have a public stock price. However, you may access SutroVax’s private market stock price with Forge Data.
What is SutroVax’s stock ticker symbol?
SutroVax does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

SutroVax Raises $110M in Series D Financing | FinSMEs
SutroVax, a Foster City, Calif.-based biopharmaceutical company dedicated to the delivery of novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, closed a $110m Series D financing
SutroVax Raises $85M in Series C Financing |FinSMEs
SutroVax, a vaccine platform and development company, closed an $85m Series C financing. The round was led by TPG Growth, with participation from Medicxi and Foresite Capital and Abingworth, Longitude Capital, Frazier Health Care Partners, Pivotal bioVenture Partners, Roche Venture Fund, and CTI Life Sciences Fund
SutroVax : Announces $85M Series C Financing led by TPG Growth
Updated on: Apr 15, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.